Ambry Genetics Announces the Addition of Illumina HiSeq 2000 and First 510(K) Approved BeadXpress(R) to Its Sequencing and Genotyping Capabilities

ALISO VIEJO, Calif., Aug. 25 /PRNewswire/ -- Ambry Genetics, a global leader in genomic services, announced today that it has acquired the Illumina HiSeq 2000 Next Generation Sequencing System as well as received the first 510(K) approved Illumina BeadXpress Genotyping System. Ambry Genetics has been an early adapter of Illumina systems since late 2007 and has extensive experience as a Certified Service Provider. A team of scientists routinely process libraries for all available applications ranging from small RNAs to whole genome DNA sequencing. Ambry has gained a solid reputation for quality data and service as well as flexibility in customizing projects to meet the specific needs of researchers.

(Logo: http://photos.prnewswire.com/prnh/20090428/LA06744LOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090428/LA06744LOGO)

The addition of the HiSeq 2000 will allow Ambry Genetics to run large projects for its customers while saving costs and providing the fastest turn-around times for sequencing. Ambry Genetics has an experienced bioinformatics team that can generate custom reports, providing flexible and results-driven informatics for sequencing projects. In addition to sequencing, Ambry Genetics currently offers diverse options for researchers interested in sequence capture / target enrichment by utilizing Agilent Technologies SureSelect, RainDance Technologies and Roche Nimblegen.

The new Illumina BeadXpress adds high-throughput genotyping capabilities to Ambry Genetics' existing line of services. The BeadXpress uses GoldenGate assays on the VeraCode technology which provides researchers with accuracy, flexibility and scalability for their projects. The system supports high level variant plexing and can process up to 96 samples per plate, which can dramatically reduce the cost of genotyping assays and deliver rapid turn-around times.

About Ambry Genetics -Ambry Genetics is a CAP-accredited and CLIA-certified commercial clinical laboratory headquartered in Aliso Viejo, California. Since the company's inception in 2000, it has become a leader in providing genetic services focused on clinical diagnostics and genomic services. Ambry has built a solid reputation for unparalleled service, and has been at the forefront of applying new technologies to the clinical molecular diagnostics market and advancements in disease research. To learn more about testing and services available through Ambry, visit www.ambrygen.com

SOURCE Ambry Genetics